Navigation Links
ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
Date:12/4/2012

PARIS, December 4, 2012 /PRNewswire/ --

ObeTherapy, a company focusing on the treatment of obesity and type II diabetes,  announces the publication of results that validate a new therapeutic target associated with  "starvation" human phenotype and a novel small-molecule candidate for the treatment of obesity and type II diabetes,

The article, entitled: Enteropeptidase: a gene associated with a starvation human phenotype and a novel target for obesity treatment, http://dx.plos.org/10.1371/journal.pone.0049612, Numerous genes associated with obesity have been targeted over the years to treat such a condition. However, none of these has provided an effective treatment for either obesity or type II diabetes.  Many commercial drugs that target such genes have been withdrawn from the market on accounts of lack of efficacy, lack of specificity, and/or toxicity. It is therefore essential to identify new gene targets that are specific, non-redundant and associated to lean phenotype.  

Research at ObeTherapy aims to identify genes that are implicated in a "lean" human phenotype by addressing the following questions:  Are there any genetic diseases that produce a "lean phenotype"? If so, is such a condition dependent upon a single gene (i.e., is it a monogenic disease)? Is such a gene tissue-specific? Is it redundant?

Congenital enteropeptidase deficiency is an extremely rare pathology that satisfies the foregoing criteria.  Patients suffering from such a condition can eat ad libitum without gaining weight; indeed, if left untreated, they will lose weight and ultimately starve (starvation phenotype).  Thus, partial inhibition of enteropeptidase with an approriate drug should allow obese patients to nourish themselves normally, yet assimilate only a fraction of the total energy consumed during a meal. These patients would thus retain the pleasure of eating while losing weight, greatly facilitating the changes in personal habits that may be required for a long-term solution to their condition.

The CEO and founder of the Company, Dr. Itzik Harosh, explained that enteropeptidase is a peripheral enzyme localized on the epithelial surface of the duodenum. This constitutes a major advantage over a systemic target, in that an inhibitor needs not be absorbed to express its activity, minimizing the probability of toxicity and side effects. This new approach of identification new targets based on «lean or starvation phenotype» should open new avenues in obesity and diabetes drug discovery.

A novel, orally administered enteropeptidase inhibitor shows very promising results in vivo. This compound is a pseudopeptide with negligible bioavailability.  Furthermore, if injected directly in the bloodstream, it is destroyed and cleared within minutes.  Few, if any, side effects are thus anticipated.

Professor Marco A. Ciufolini, of the University of British Columbia at Vancouver, and a consultant in synthetic chemistry for Obetherapy, indicated that the inhibitor in question can be manufactured on large scale after only minor modifications of the current route. 

Dr. Harosh declared that these results should promote the development of the company and assist ObeTherapy in establishing new collaborations and fund raising.

Obetherapy Biotechnology is a company specializing in the research and development of new drugs for the treatment of obesity, hypercholesterolemia, and type II diabetes. It is localized on the Génopôle® campus, in Evry, France.  Unlike its competitors, who concentrate on the genetic characterization of obesity, ObeTherapy follows an innovative approach that centers on the analysis of individuals with a "lean" phenotype. The Company is especially interested in the study of patients suffering from rare monogenic diseases characterized by a deficiency in the absorption fats and proteins, which are major sourses of energy.

About Genopole®

Genopole®  French biopark dedicated to research in genetics and biotech for healthcare and the environment. It brings together 20 academic laboratories, 73 biotech companies, 18 shared-use technology platforms and university teaching facilities. The biopark's objectives are to promote research in genomics, post-genomics & related sciences, transfer technology to industry, develop high-level life science teaching & training and foster the creation and growth of biotech companies. http://www.genopole.fr/?lang=en


'/>"/>
SOURCE ObeTherapy Biotechnology
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... 25, 2017 Endo International plc (NASDAQ: ENDP ... Members of its senior management team will host a conference call ... ET. The dial-in number to access the call ... and the passcode is 6086379. Please dial in 10 minutes prior ... A replay of the call will be available from May 9, ...
(Date:4/24/2017)... SW Safety Solutions, Inc., the industry,s leader ... release of the latest advancement in workplace single-use gloves ... leading edge nitrile glove technology features SW,s patent pending ... grip on wet and oily surfaces and the highest ... a suite of other advanced SW technologies, the Powerform,s ...
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
Breaking Medicine Technology:
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... support, and collaboration, announces Mirroring360 Pro . This new addition to the ... collaboration experience for education and business. , Mirroring360 Pro enables educators, business professionals ...
(Date:4/25/2017)... ... 25, 2017 , ... Coalition Duchenne, a ... muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on positive ... trial in Duchenne announced today. , Coalition Duchenne funded studies carried out ...
(Date:4/25/2017)... Indianapolis, IN (PRWEB) , ... April 25, 2017 ... ... Washington, D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration ... Life Financial will provide insight into what changes are most likely to make ...
(Date:4/25/2017)... , ... April 25, 2017 , ... The doctors at ... BC, who live with dental fear and require sedation to receive dental care. The ... ease during various procedures, from hygienic cleanings to oral surgery, at their dental office ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would ... results in a fraction of the time as traditional braces – Wilckodontics®. Dr. ... Specialists, now offers this revolutionary treatment with or without a referral. , ...
Breaking Medicine News(10 mins):